@trackerbiobank.bsky.social📣 Poster P2.141 | #WCLC2026
Heading to the poster sessions in Seoul today?
Be sure to look out for Dr Sarah Yeo, TRACKER PhD Candidate, presenting her work on EBUS-TBNA-derived whole-exome copy-number burden and immunotherapy response in advanced lung cancer.
@cancertherapyadv.bsky.socialPrimary analysis of the Phase 2 MDT-BRIDGE study presented at WCLC 2026 shows encouraging outcomes for perioperative durvalumab + chemotherapy in stage IIB–IIIB #NSCLC 🫁
Presented by Dr Martin Reck at #WCLC2026 @iaslc.bsky.social
Read the article: https://bit.ly/4cKEb2H
@medchemexpress.bsky.social💊 #WCLC 2026 | Key Advances in #LungCancer Research
From B7-H3 ADCs to next-generation TKIs and combination strategies, WCLC 2026 highlights evolving approaches in #NSCLC and #SCLC:
🔗https://bit.ly/4xW10sT
@trackerbiobank.bsky.social🌏🔬 TRACKER PhD Candidate Dr Sarah Yeo is in Seoul for #WCLC2026, supported by the Rosemary Holmes Travel Grant from Lung Foundation Australia
If you’re at WCLC, make sure to catch Sarah presenting in the Pathology & Biomarker session today!
@cancers-mdpi.bsky.social📸 Great catching up with so many esteemed researchers and experts in the lung cancer community at #WCLC2026!
If you are at the conference, drop by booth #706 to connect with our team! ✨
#LungCancer #CancersMDPI #Oncology @iaslc.bsky.social
@cancers-mdpi.bsky.socialLive from #WCLC26! 📸 Our team is all set at Booth #706. Drop by to connect, share insights, and discuss the latest in lung cancer research. We’d love to meet you! 💞
#IASLC #LungCancer #WCLC2026 @iaslc.bsky.social
@lungcancereurope.bsky.socialOur President joined speakers from across the lung cancer community at #WCLC2026 today for From Evidence to Action: Practical Skills for Engaging Policymakers on Earlier #LungCancer Detection.
She spoke about handling objections to
screening & how advocates can respond when concerns are raised.
